title: NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
abstract: Animal models of multiple myeloma vary in terms of consistency of onset, degree of tumour burden and degree of myeloma bone disease. Here we describe five pre-clinical models of myeloma in NOD/SCID-GAMMA mice to specifically study the effects of therapeutic agents on myeloma bone disease. Groups of 7-8 week old female irradiated NOD/SCID-GAMMA mice were injected intravenously via the tail vein with either 1x106 JJN3, U266, XG-1 or OPM-2 human myeloma cell lines or patient-derived myeloma cells. At the first signs of morbidity in each tumour group all animals were sacrificed. Tumour load was measured by histological analysis, and bone disease was assessed by micro-CT and standard histomorphometric methods. Mice injected with JJN3, U266 or OPM-2 cells showed high tumour bone marrow infiltration of the long bones with low variability, resulting in osteolytic lesions. In contrast, mice injected with XG-1 or patient-derived myeloma cells showed lower tumour bone marrow infiltration and less bone disease with high variability. Injection of JJN3 cells into NOD/SCID-GAMMA mice resulted in an aggressive, short-term model of myeloma with mice exhibiting signs of morbidity 3 weeks later. Treating these mice with zoledronic acid at the time of tumour cell injection or once tumour was established prevented JJN3-induced bone disease but did not reduce tumour burden, whereas, carfilzomib treatment given once tumour was established significantly reduced tumour burden. Injection of U266, XG-1, OPM-2 and patient-derived myeloma cells resulted in less aggressive longer-term models of myeloma with mice exhibiting signs of morbidity 8 weeks later. Treating U266-induced disease with zoledronic acid prevented the formation of osteolytic lesions and trabecular bone loss as well as reducing tumour burden whereas, carfilzomib treatment only reduced tumour burden. In summary, JJN3, U266 or OPM-2 cells injected into NOD/SCID-GAMMA mice provide robust models to study anti-myeloma therapies, particularly those targeting myeloma bone disease.
authors.affiliation: Department of Oncology, University of Sheffield, Sheffield, United Kingdom; Mellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom.
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Lawson
authors.affiliation: Department of Oncology, University of Sheffield, Sheffield, United Kingdom; Mellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom.
authors.forename: Julia M
authors.initials: JM
authors.lastname: Paton-Hough
authors.affiliation: Department of Oncology, University of Sheffield, Sheffield, United Kingdom; Mellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom.
authors.forename: Holly R
authors.initials: HR
authors.lastname: Evans
authors.affiliation: Department of Oncology, University of Sheffield, Sheffield, United Kingdom; Mellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom.
authors.forename: Rebecca E
authors.initials: RE
authors.lastname: Walker
authors.affiliation: Department of Oncology, University of Sheffield, Sheffield, United Kingdom; Mellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom.
authors.forename: William
authors.initials: W
authors.lastname: Harris
authors.affiliation: Department of Oncology, University of Sheffield, Sheffield, United Kingdom; Mellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom.
authors.forename: Dharshi
authors.initials: D
authors.lastname: Ratnabalan
authors.affiliation: Department of Oncology, University of Sheffield, Sheffield, United Kingdom; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, United Kingdom.
authors.forename: John A
authors.initials: JA
authors.lastname: Snowden
authors.affiliation: Department of Oncology, University of Sheffield, Sheffield, United Kingdom; Mellanby Centre for Bone Research, University of Sheffield, Sheffield, United Kingdom; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, United Kingdom.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Chantry
mesh_terms: D000818:Animals; D001847:Bone Diseases / Q000188:drug therapy* / Q000473:pathology*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology; D004164:Diphosphonates / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology*; D009368:Neoplasm Transplantation / Q000473:pathology; D009842:Oligopeptides / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D009842:Oligopeptides; D000077211:Zoledronic Acid; C524865:carfilzomib